Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test MPN Prognostication & Risk Stratification Panel is 14 days.

What are the prerequisites for the test MPN Prognostication & Risk Stratification Panel

  • Diagnosis of Myeloproliferative Neoplasm (MPN)
  • Baseline CBC (Complete Blood Count)
  • Baseline Bone Marrow Biopsy
  • Baseline molecular testing results (if available)
  • Any relevant clinical history or symptoms

What are the measure values for the test MPN Prognostication & Risk Stratification Panel

  • BCR-ABL1 gene rearrangement: Positive or Negative
  • JAK2 V617F mutation: Positive or Negative
  • CALR mutation: Positive or Negative
  • MPL mutation: Positive or Negative
  • CSF3R mutation: Positive or Negative
  • ASXL1 mutation: Positive or Negative
  • EZH2 mutation: Positive or Negative
  • TP53 mutation: Positive or Negative
  • IDH1 mutation: Positive or Negative
  • IDH2 mutation: Positive or Negative

What does this test MPN Prognostication & Risk Stratification Panel identify?

Test MPN Prognostication & Risk Stratification Panel

This panel is used to identify the prognosis and risk stratification for patients with Myeloproliferative Neoplasms (MPNs). It includes a combination of genetic tests, imaging studies, and blood tests to determine the severity of the disease and the likelihood of progression.

  • JAK2 V617F Mutation Analysis: This test identifies the presence of a specific mutation in the JAK2 gene, which is commonly found in patients with MPNs. The presence of this mutation can indicate a higher risk of disease progression.
  • CBC with Differential: A complete blood count with a focus on the differential count can provide information on the levels of different types of blood cells, which can help in assessing the severity of the disease and the risk of complications.
  • Bone Marrow Biopsy: A bone marrow biopsy is performed to evaluate the morphology and cellularity of the bone marrow, which can help in determining the stage of the disease and the risk of progression.
  • Cytogenetic Analysis: This test looks for abnormalities in the chromosomes of the blood cells, which can provide additional information on the prognosis and risk of developing complications.

Why is this test MPN Prognostication & Risk Stratification Panel taken?

Reason for taking the MPN Prognostication & Risk Stratification Panel

The MPN Prognostication & Risk Stratification Panel test is taken to assess the prognosis and risk stratification of patients with myeloproliferative neoplasms (MPNs). MPNs are a group of rare blood cancers that affect the bone marrow and lead to the overproduction of blood cells.

This panel of tests helps in determining the severity of the disease, predicting the progression of the MPN, and guiding treatment decisions. It includes various markers and genetic mutations that are associated with different risk levels and outcomes in MPN patients.

Overall, the MPN Prognostication & Risk Stratification Panel is essential for oncologists and hematologists to tailor personalized treatment plans for MPN patients based on their individual risk factors and prognosis.

No FAQs available.

Customer Google Rating